ATM and B-cell chronic lymphocytic leukemia: Three completed Phase I/II clinical trials recently evaluated ceralasertib as a single agent in relapsed/refractory ATM-deficient chronic lymphocytic leukemia (CLL), in combination with paclitaxel for non-responsive metastatic cancer, and in combination with olaparib for relapsed small cell lung cancer (SCLC).